Monica Milano, Carmine Valenza, Nadia Bianco, Simona Manacorda, Matteo Cavallone, Letizia Matera, Renato Maria Marsicano, Elena Battaiotto, Pier Paolo Maria Berton Giachetti, Edoardo Giordano, Julian David Etessami, Dario Trapani, Simone Schena, Claudia Sangalli, Sabrina Kahler Ribeiro Fontana, Sara Gandini, Paolo Veronesi, Viviana Galimberti, Marco Colleoni, Giuseppe Curigliano, Elisabetta Munzone
{"title":"Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study.","authors":"Monica Milano, Carmine Valenza, Nadia Bianco, Simona Manacorda, Matteo Cavallone, Letizia Matera, Renato Maria Marsicano, Elena Battaiotto, Pier Paolo Maria Berton Giachetti, Edoardo Giordano, Julian David Etessami, Dario Trapani, Simone Schena, Claudia Sangalli, Sabrina Kahler Ribeiro Fontana, Sara Gandini, Paolo Veronesi, Viviana Galimberti, Marco Colleoni, Giuseppe Curigliano, Elisabetta Munzone","doi":"10.1016/j.eclinm.2026.104174","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Evidence regarding outcomes in patients with hormone receptor (HR)-positive/HER2-negative breast cancer (BC) with a second consecutive ipsilateral locoregional recurrence (LRR) remains limited.</p><p><strong>Methods: </strong>Single-center, cohort study including consecutive patients with HR-positive/HER2-negative BC who underwent surgery (study baseline) for a second consecutive, ipsilateral LRR, at the European Institute of Oncology (Milan) from January 2001 to September 2025. Endpoints included invasive breast cancer-free survival (IBCFS) and distant recurrence-free survival (DRFS).</p><p><strong>Findings: </strong>111 patients were included: median age at study baseline was 61 years. The second LRR occurred in the breast in 44% of patients, in locoregional lymph nodes in 23%, on the mastectomy scar or chest wall in 31%. Endocrine-resistant recurrence was observed in 69% of patients. Overall, 14% of patients received adjuvant chemotherapy and 5% a CDK4/6-inhibitor. At a median follow-up of 6.3 years (95% CI: 4.7-7.9), 57 IBCFS events and 40 DRFS events were reported. Median IBCFS was 6.8 years (95% CI: 4.8-7.6) and median DRFS was 9.6 years (95% CI: 6.9-Not Reached [NR]). Median IBCFS was longer in endocrine-sensitive compared to endocrine-resistant LRR (8.6 years [95% CI: 4.6-NR] vs. 5.3 years [95% CI: 4.0-6.9]), and in intraparenchymal LRR (6.8 years [95% CI: 4.8-NR]) compared to nodal (6.4 years [95% CI: 1.4-NR]) or chest wall (5.1 years [95% CI: 4.0-NR]) recurrence.</p><p><strong>Interpretation: </strong>Among patients experiencing a second consecutive LRR, approximately 50% develop a subsequent IBCFS event within 7 years, supporting consideration of treatment intensification, particularly in endocrine-resistant disease or recurrence involving the chest wall or regional lymph nodes.</p><p><strong>Funding: </strong>None.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"99 ","pages":"104174"},"PeriodicalIF":12.8000,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13562386/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2026.104174","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Evidence regarding outcomes in patients with hormone receptor (HR)-positive/HER2-negative breast cancer (BC) with a second consecutive ipsilateral locoregional recurrence (LRR) remains limited.
Methods: Single-center, cohort study including consecutive patients with HR-positive/HER2-negative BC who underwent surgery (study baseline) for a second consecutive, ipsilateral LRR, at the European Institute of Oncology (Milan) from January 2001 to September 2025. Endpoints included invasive breast cancer-free survival (IBCFS) and distant recurrence-free survival (DRFS).
Findings: 111 patients were included: median age at study baseline was 61 years. The second LRR occurred in the breast in 44% of patients, in locoregional lymph nodes in 23%, on the mastectomy scar or chest wall in 31%. Endocrine-resistant recurrence was observed in 69% of patients. Overall, 14% of patients received adjuvant chemotherapy and 5% a CDK4/6-inhibitor. At a median follow-up of 6.3 years (95% CI: 4.7-7.9), 57 IBCFS events and 40 DRFS events were reported. Median IBCFS was 6.8 years (95% CI: 4.8-7.6) and median DRFS was 9.6 years (95% CI: 6.9-Not Reached [NR]). Median IBCFS was longer in endocrine-sensitive compared to endocrine-resistant LRR (8.6 years [95% CI: 4.6-NR] vs. 5.3 years [95% CI: 4.0-6.9]), and in intraparenchymal LRR (6.8 years [95% CI: 4.8-NR]) compared to nodal (6.4 years [95% CI: 1.4-NR]) or chest wall (5.1 years [95% CI: 4.0-NR]) recurrence.
Interpretation: Among patients experiencing a second consecutive LRR, approximately 50% develop a subsequent IBCFS event within 7 years, supporting consideration of treatment intensification, particularly in endocrine-resistant disease or recurrence involving the chest wall or regional lymph nodes.
期刊介绍：
eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
